Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?
Abstract Objectives To assess whether free PSA ratio (FPSAR) at biochemical recurrence (BCR) can predict metastasis, castrate‐resistant PCa (CRPC), and cancer‐specific survival (CSS), following therapy for localized disease. Methods A single‐center retrospective cohort study (NCT03927287) including a discovery cohort composed of patients with an FPSAR after radical prostatectomy (RP) or radiotherapy (RT) between 2000‐2017. For […]